• Quizartinib 17.7mg

Quizartinib 17.7mg

SKU:52165

Quizartinib is used with standard chemotherapy and then as maintenance treatment for adults with newly diagnosed acute myeloid leukaemia that is FLT3-ITD positive.

Usual adult dose range: 17.7mg to 53mg once daily, with 35.4mg once daily used during chemotherapy cycles and 26.5mg to 53mg once daily used during maintenance, depending on heart rhythm monitoring.


Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.


  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.